​
​

FSD Pharma Stock (NASDAQ:HUGE)

OwnershipFinancialsChart
FSD Pharma by TradingView

Previous Close

$0.10

52W Range

$0.09 - $109.19

50D Avg

$8.13

200D Avg

$36.69

Market Cap

$66.67K

Avg Vol (3M)

$196.16K

Beta

0.85

Div Yield

-

HUGE Company Profile

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

17

IPO Date

Jun 08, 2018

Website

HUGE Performance

HUGE Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-19.93M$-27.43M$-33.74M
Net Income$-18.56M$-23.32M$-35.41M
EBITDA$-17.38M$-22.41M$-29.65M
Basic EPS$-0.47$-0.60$-1.01
Diluted EPS$-0.47$-0.60$-1.01

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
BFRIBiofrontera Inc.
ACORAcorda Therapeutics, Inc.
LSDILucy Scientific Discovery Inc.
SXTCChina SXT Pharmaceuticals, Inc.